PASI Improvement in the First 12 Weeks from the Phase 3 VOYAGE 1, VOYAGE 2, ORION, and ECLIPSE Guselkumab Clinical Trials

    September 2023 in “ Journal of the American Academy of Dermatology ”
    Kim Papp, Ronald Vender, Richard G. Langley, Vincent Ho, Laura Park- Wyllie, Nastaran Abbarin, Mitchell D. Miller, Yin You, Ya-Wen Yang
    Studysummary This study evaluated the effect of guselkumab on moderate to severe plaque psoriasis and found that median PASI improvements increased from around 60% at week 4 to over 90% by week 12 of treatment across multiple clinical trials. Our plain-language summary of this paper — not a Tressless recommendation.
    The Phase 3 clinical trials VOYAGE 1, VOYAGE 2, ORION, and ECLIPSE evaluated the efficacy of guselkumab in treating moderate to severe plaque psoriasis. Across these trials, a total of 1,421 subjects were randomized to receive guselkumab. The study found that median PASI improvements were approximately 60% at Week 4, except for the ORION trial, and increased to over 90% by Week 12 after the second dose. These results indicate a significant and rapid onset of action for guselkumab in improving psoriasis symptoms within the first 12 weeks of treatment.
    Discuss this study in the Community →